The European First Episode Schizophrenia Trial (EUFEST): Comparison of outcome in The European study of the effectiveness of haloperidol, amisulpride . The study helps solve the question of which category of antipsychotic medications best address impaired cognition, which affects a significant. The EUFEST study then undertook with a pragmatic open randomized-controlled trial design to compare the effectiveness of second-generation antipsychotic.

Author: Mooguran Nera
Country: Equatorial Guinea
Language: English (Spanish)
Genre: Software
Published (Last): 26 April 2005
Pages: 470
PDF File Size: 10.86 Mb
ePub File Size: 19.33 Mb
ISBN: 939-4-76555-522-8
Downloads: 27530
Price: Free* [*Free Regsitration Required]
Uploader: Doulkis

The Lancet ; This effort represents the first independently designed trans-European schizophrenia treatment trial. Result of results found for within.

Plain English Summary Not provided at time of registration Trial website http: Retention to allocated study drug, which is the time that the patient stays on the randomised drug within the study dose range.

Eufdst aimed to compare the effectiveness of second-generation antipsychotic drugs with that of a low dose of haloperidol, in first-episode schizophrenia. PfizerAstraZenecaSanofi-Aventis. Ethics approval Ethics approval received from the local medical ethics committee Study design Multicentre, randomised active controlled, parallel group trial Primary study design Atudy Secondary study design Randomised controlled trial Trial setting Hospitals Trial type Treatment Patient information sheet Condition Schizophrenia, schizophreniform, or schizoaffective disorder Intervention Drug: Patients and their treating physicians were not blinded to the assigned treatment.

Previous Rufest Back to results Next Trial. The aim of the European First Episode Schizophrenia Trial EUFEST is to compare treatment with amisulpride, quetiapine, olanzapine and ziprasidone to a low dose of haloperidol in an unselected sample of first episode schizophrenia patients with minimal prior exposure to antipsychotics.

Most studies comparing second generation antipsychotics with classical neuroleptics have been conducted in more or less chronic schizophrenia patients. Comparisons with haloperidol showed lower risks for any-cause discontinuation with amisulpride hazard ratio [HR] 0.

  DERECHO INTERNACIONAL PUBLICO LORETTA ORTIZ PDF

At regular time intervals patients are euufest until 12 months after recruitment: Diagnosis of schizophrenia, schizophreniform or schizoaffective disorder 2. The principal investigators are Prof.

The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial.

At present, more than patients have been recruited and randomized in the following countries: SchizophreniaSchizophreniform disorderSchizoaffective disorder. The primary outcome measure is retention in treatment, defined as time to discontinuation of study drug. Genetic determinants of response to antipsychotic drugs 9. Psychopathology – positive sudy, negative symptoms, depression, agitation-excitement, disorganisation 2.

Eligibility Participant inclusion criteria 1.

The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial.

Study information Scientific title The European study of the effectiveness of haloperidol, amisulpride, olanzapine, quetiapine, and ziprasidone on loss of retention in first episode schizophrenia Acronym EUFEST Study hypothesis What is the effectiveness of low doses of haloperidol and regular doses of amisulpride, olanzapine, quetiapine, and ziprasidone on loss of one year retention in patients with recent onset of schizophrenia, schizoaffective, and schizophreniform disorder?

Intolerance to one of the drugs in this study; 4. Retention to allocated study drug, which is the time that the patient stays on the randomised drug within the study dose range. Diagnosis of schizophrenia; 2. However, we cannot conclude that second-generation drugs are more efficacious than is haloperidol, since discontinuation rates are not necessarily consistent with symptomatic improvement.

The European study of the effectiveness of haloperidol, amisulpride, olanzapine, quetiapine, and ziprasidone on loss of retention in first episode schizophrenia.

Quality of life 6. Schizophreniform or schizoaffective disorder; 3.

Amisulpride, Haloperidol, Olanzapine, Quetiapine, Ziprasidone. Side effects – extrapyramidal symptoms EPS side-effect profile, sexual side effects and weight gain 3.

The presence of one or more of the tsudy against any of the study drugs. Natural history of schizophrenia. Ethics approval received from the local medical ethics committee.

  AKHBAR AL AKHYAR URDU PDF

Results and Publications Publication and dissemination plan Not provided at time of registration Intention to publish date Participant level data Not provided at time of registration Basic results scientific Publication list 1. EUFEST assesses the effectiveness of a low dose of haloperidol versus regular doses of 4 second generation antipsychotics: Home Who are we?

Second-generation antipsychotic drugs were introduced over a decade ago for the treatment of schizophrenia; however, their purported clinical effectiveness compared with first-generation antipsychotic drugs is still debated.

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: These and other facts have stimulated discussions regarding the effectiveness of the new generation of antipsychotics.

This pragmatic trial suggests that clinically meaningful antipsychotic studh of first-episode of schizophrenia is achievable, for at least 1 year. Loss of retention can be the result of insufficient clinical effect, or lack of tolerability or acceptance.

We focus on the real world treatment of first episode patients by enrolling heterogeneous patient populations, including patients who show comorbid drug abuse or who are aggressive or suicidal or less likely to be compliant with treatment.

The study should be finished by the end of and it is expected that results will yield relevant clinical information with regard to the effectiveness of the second generation antipsychotics. The European study of the effectiveness of haloperidol, amisulpride, olanzapine, quetiapine, and ziprasidone on loss of retention in first episode schizophrenia.

Eligible patients were aged years, and met diagnostic criteria for schizophrenia, schizophreniform disorder, or schizoaffective disorder.